As of December 31, 2025, Zhengye Biotechnology Holding Limited carries a market capitalization of 54.50M, placing it among publicly traded companies globally. Its enterprise value stands at 65.95M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 54.50M |
| Enterprise Value | 65.95M |
As of December 31, 2025, Zhengye Biotechnology Holding Limited has 47.39M shares outstanding.
| Shares Outstanding | 47.39M |
These figures are as of December 31, 2025.
| PB Ratio | 1.53 |
| P/TBV Ratio | 1.95 |
As of December 31, 2025, Zhengye Biotechnology Holding Limited maintains a current ratio of 1.14, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.14 |
| Quick Ratio | 0.58 |
| Debt / Equity | 24.48 |
These figures cover the twelve months ended December 31, 2025.
| Employee Count | 273.00 |
As of the close on November 16, 2026, Zhengye Biotechnology Holding Limited's stock has declined approximately 35.01% over the past 52 weeks. The 50-day moving average sits at 1.41, while the 200-day moving average is 1.18.
| 52-Week Price Change | -35.01% |
| 50-Day Moving Average | 1.41 |
| 200-Day Moving Average | 1.18 |
As of December 31, 2025, Zhengye Biotechnology Holding Limited holds 7.42M in cash and equivalents against 10.74M in total debt, resulting in a net debt position of 3.48M. Total book value stands at 35.73M, with working capital of 2.42M providing operational flexibility.
| Cash & Cash Equivalents | 7.42M |
| Total Debt | 10.74M |
| Net Debt | 3.48M |
| Equity (Book Value) | 35.73M |
| Book Value Per Share | 0.75 |
| Working Capital | 2.42M |
Already premium?